To the full analysis
Ipca Laboratories stock: growth
IPCALAB.NSIpca Laboratories reported $1.03B in revenue for fiscal 2026, up 7.9% on the prior year, up 12.2% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
13%
per year from 2007 to 2026, per share 13%
Earnings (Annual rate)
12.3%
per year from 2007 to 2026, per share 12.2%
Free cash flow (Annual rate)
16.7%
per year from 2007 to 2026, per share 16.6%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2021 | since 2016 | since 2007 | |
|---|---|---|---|
| Revenue | 12.2% | 12.9% | 13.0% |
| Revenue per share | 12.2% | 12.8% | 13.0% |
| Earnings | 0.0% | 28.5% | 12.3% |
| Earnings per share | 0.0% | 28.4% | 12.2% |
| Free cash flow | −7.8% | 0.5% | 16.7% |
| Free cash flow per share | −7.8% | 0.5% | 16.6% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2007 | $99.82M | $13.41M | $2.76M |
| 2008 | $111.74M | $14.45M | −$4.02M |
| 2009 | $136.45M | $10.71M | $6.65M |
| 2010 | $165.76M | $21.83M | $6.08M |
| 2011 | $201.93M | $27.93M | $1.63M |
| 2012 | $250.71M | $29.36M | $9.92M |
| 2013 | $299M | $34.39M | $16.94M |
| 2014 | $348.81M | $50.86M | $15.16M |
| 2015 | $334.21M | $27.02M | −$9.58M |
| 2016 | $304.74M | $9.9M | $49.05M |
| 2017 | $335.47M | $20.68M | $15.47M |
| 2018 | $349.18M | $25.45M | $21.73M |
| 2019 | $401.23M | $47.28M | $34.06M |
| 2020 | $494.23M | $64.44M | $28.07M |
| 2021 | $576.16M | $121.17M | $77.44M |
| 2022 | $619.72M | $93.97M | $40.08M |
| 2023 | $664.1M | $50.1M | $33.09M |
| 2024 | $819.05M | $58.18M | $56.69M |
| 2025 | $950.35M | $78.41M | $53.09M |
| 2026 | $1.03B | $121.29M | $51.66M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ₹94.0836)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 13 Nov 2026, previously Strong
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.